Long-term follow-up from a phase Ib trial in newly diagnosed and previously treated patients with advanced melanoma showed that 40 percent of patients were alive three years after starting Keytruda (pembrolizumab), with similar 36-month overall survival rates in both groups.
Results from a pre-specified interim analysis from the phase III J-ALEX study found that Alecensa (alectinib) reduced the risk of disease worsening or death by 66 percent compared to (Xalkori) crizotinib in Japanese people with advanced or recurrent ALK-positive non-small cell lung cancer (HR=0.34, 99% CI: 0.17-0.70, p<0.0001) who had not received prior treatment with an ALK inhibitor.
FDA granted accelerated approval to Tecentriq (atezolizumab) for urothelial carcinoma, the most common type of bladder cancer. This is the first product in its class of PD-1/PD-L1 inhibitors approved to treat this type of cancer, according to the drug's sponsor, Genentech.
A retrospective analysis found that the location of the primary tumor within the colon predicts survival and may help inform optimal treatment selection for patients with metastatic colorectal cancer.
Early findings from a phase III clinical trial showed that patients with multiple myeloma who received an autologous stem cell transplant survived longer without disease progression than those who received only chemotherapy using novel agents.
ProNAi Therapeutics, Inc. obtained an exclusive license from Carna Biosciences Inc. in Japan for worldwide rights to develop and commercialize AS-141, a small molecule kinase inhibitor targeting CDC7. Under the terms of the agreement, ProNAi will pay Carna Biosciences an initial upfront payment of $0.9 million and aggregate additional potential payments upon achievement of certain... […]
The European Medicines Agency Committee for Medicinal Products for Human Use adopted a positive opinion to extend the indication for Kyprolis (carfilzomib) to include treatment in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.
LIGHTPOINT MEDICAL signed an exclusive global license agreement for Beta Emission Tomography molecular imaging technology, developed by Harrison Barrett, regents professor of radiology and optical science, with his student Yijun Ding and colleague Luca Caucci at the University of Arizona Center for Gamma Ray Imaging. Barrett and his team have developed a novel approach to... […]
THE AMERICAN SKIN ASSOCIATION presented several awards for cancer research during the annual meeting of the Society for Investigative Dermatology. Barbara Gilchrest, of Harvard Medical School and Massachusetts General Hospital, received the David Martin Carter Mentor Award. Gilchrest is the editor-in-chief of The Journal for Investigative Dermatology and former president of both the Society for... […]
UNIVERSITY OF CHICAGO MEDICINE and Blue Cross and Blue Shield of Illinois launched an oncology intensive medical home program. The UCMedicine IMH will treat qualifying PPO patients receiving chemotherapy for a cancer diagnosis of breast, colon, lung, pancreatic, prostate and non-Hodgkin’s lymphoma. “In conjunction with the oncologists at UCMedicine, we will be utilizing the latest... […]
